Custom Search


Saturday 01 December 2001

Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.

By: Tumolo S, Toffoli G, Saracchini S, Lo Re G, Bruschi G, Boccieri MG.

Lung Cancer 2001 Dec;34 Suppl 4:S37-46

In the last years, the main topoisomerase I inhibitors (TP1-I) (i.e. topotecan and irinotecan) have been used in combination chemotherapy in non-small cell lung cancer. Several drugs (also alternative to cisplatin) have been used in combination with TP1-I, but to date the higher remission rate obtained with combinations is not translated into a more prolonged survival in comparison with TP1-I given alone. On the other hand, the toxicity of TP1-I combinations is greater than those of TP1-I used alone. The superior efficacy of combinations versus TP1-I used alone remains an open question. Furthermore, the best schedule for TP1-I has not been completely elucidated. Randomised studies are few (only two phase III trials) and only controlled studies will be able to clarify the best TP1-I combination regimen.

Use of this site is subject to the following terms of use